Health Minister Mandaviya delivers keynote address 2nd Voice of Global South Summit 2023

Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure

FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients

Innocan Pharma reports discovery regarding its LPD platform and global CBD research

The company expects that this development could improve the strength of its application to the FDA for new drug approval

Need to include ASMD as a notified condition in the National Policy for rare diseases

ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months